



# HCC: Key Journal Articles and Abstracts

[Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. \*N Engl J Med.\* 2018;379\(1\):54-63.](#)

[Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment \(RESORCE\): a randomised, double-blind, placebo-controlled, phase 3 trial. \*Lancet.\* 2017;389\(10064\):56-66.](#)

[El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma \(CheckMate 040\): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. \*Lancet.\* 2017;389\(10088\):2492-2502.](#)

[Finn RS, Merle P, Granito A, et al. Outcomes with sorafenib \(SOR\) followed by regorafenib \(REG\) or placebo \(PBO\) for hepatocellular carcinoma \(HCC\): results of the international, randomized phase 3 RESORCE trial. 2017;35\(4 suppl\):Abstract 344.](#)

[Hsu CY, Liu PH, Lee YH, et al. Using serum  \$\alpha\$ -fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? \*PLoS One.\* 2015;10\(3\):e0118825.](#)

[Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. \*Lancet.\* 2018;391\(10126\):1163-1173.](#)

[Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. \*N Engl J Med.\* 2008;359\(4\):378-390.](#)

[Llovet JM, Yen CJ, Finn RS, et al. Ramucirumab \(RAM\) for sorafenib intolerant patients with hepatocellular carcinoma \(HCC\) and elevated baseline alpha fetoprotein \(AFP\): outcomes from two randomized phase 3 studies \(REACH, REACH2\). \*J Clin Oncol.\* 2019;37:Abstract 4073.](#)

[Zhu AX, Finn RS, Edeline J, et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib \(KEYNOTE-224\): a non-randomised, open-label phase 2 trial. \*Lancet Oncol.\* 2018;19\(7\):940-952.](#)

[Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased  \$\alpha\$ -fetoprotein concentrations \(REACH-2\): a randomised, double-blind, placebo-controlled, phase 3 trial. \*Lancet Oncol.\* 2019;20\(2\):282-296.](#)

[Zhu AX, Park JO, Ryoo BY, et al; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib \(REACH\): a randomised, double-blind, multicentre, phase 3 trial. \*Lancet Oncol.\* 2015;16\(7\):859-870.](#)